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Summary
Objective: Nitric oxide (NO) produced by cartilage and synovial membrane is implicated in the pathogenesis of osteoarthritis (OA) and
rheumatoid arthritis (RA). In inflamed joints NO is synthesized in response to proinflammatory cytokines and it is involved in the joint
destruction. The aim of the present study was to investigate the effects of TNF-antagonists infliximab and etanercept on NO production in
human cartilage.
Design: Cartilage specimen obtained from OA patients undergoing knee replacement surgery were studied for iNOS expression and NO
production in organ culture to allow intact chondrocyte–matrix interactions. TNF and soluble TNF receptor release was measured by
ELISA.
Results: Osteoarthritic cartilage produced NO spontaneously and its production was enhanced by proinflammatory cytokines TNF (tumor
necrosis factor ), IL-1 (interleukin-1), IL-17 (interleukin-17) and by bacterial lipopolysaccharide (LPS). TNF-antagonists infliximab and
etanercept inhibited TNF-induced NO production in a dose dependent manner but they had no effect on IL-1-, IL-17- and LPS-stimulated
NO synthesis. TNF and soluble TNF receptors (sTNFRI and sTNFRII) were produced by human osteoarthritic cartilage. A neutralizing
antibody against soluble TNFRI enhanced spontaneous NO production whereas an antibody against soluble TNFRII had no effect.
Conclusions: TNF-antagonists infliximab and etanercept suppressed TNF-induced NO production. This effect was not seen on IL-1-,
IL-17- or LPS-induced NO production suggesting that TNF is not an autacoid mediator in these processes. The studies with neutralizing
antibodies against soluble TNFRI suggest that endogenous cartilage-derived TNF-antagonists modulate NO production in osteoarthritic
cartilage. © 2002 OsteoArthritis Research Society International
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According to modern views, osteoarthritis (OA) is a slowly
progressing inflammatory disease, not a simple ‘wear and
tear’ phenomenon. It has been shown that cytokines
interleukin-1 (IL-1) and tumor necrosis factor  (TNF
enhance the destructive processes in osteoarthritic carti-
lage1. Both of these cytokines are also capable of inducing
the production of nitric oxide (NO) in chondrocytes2–8.
Accordingly, markers of enhanced NO production in osteo-
arthritic and rheumatoid arthritic joints have been
reported9.
A recent immunohistochemical study reported enhanced
expression of inducible NO synthase (iNOS) principally in
chondrocytes and significantly less in synovial cells in OA
patients, suggesting that chondrocytes are the major
source of NO in osteoarthritic joints10. iNOS is expressed
also in rheumatoid arthritic synovial membrane8 and in the
pseudo-synovial membrane around the loosened joint
implants11. In inflamed joints NO acts principally as a
proinflammatory and destructive mediator. NO activates327metalloproteases12, suppresses partially de novo synthesis
of collagen and proteoglycan13–17 and induces chondro-
cyte apoptosis18,19. NO is also involved indirectly in the
up-regulation of proinflammatory cytokine production in
inflamed joints by reducing the synthesis of IL-1 receptor
antagonist (IL-1Ra)20 and by increasing the production of
TNF by synovial cells21. In addition, inhibitors of NO
synthesis have been reported to relieve or even prevent the
clinical and histological findings in various models of
arthritis22–27. Furthermore, two recent articles have shown
the retardation of experimental OA by NOS inhibitors28,29.
TNF-antagonists, infliximab and etanercept, have been
recently introduced in the treatment of rheumatoid arthritis
(RA). Both of these drugs block the bioactivity of TNF.
Infliximab is a chimaeric monoclonal antibody to human
TNF and etanercept is a fusion protein containing TNF-
binding domain of the of 75 kD receptor for TNF30,31.
Anti-TNF therapy has demonstrated significant reduction
in disease activity and retardation in joint erosion in con-
trolled clinical trials in patients with RA30–32. Along with
suppressive effects on cytokines, TNF-antagonists have
been shown to decrease also iNOS expression and NO
production in RA patients33. Since TNF is implicated in the
pathogenesis of OA34 and in the up-regulation of inducible
NO synthesis35, we decided to study the effects of TNF
and TNF-antagonists infliximab and etanercept on NO
production in human osteoarthritic cartilage.
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PATIENTS, TISSUE AND CELL CULTURES
Cartilage tissue was obtained from the leftover pieces of
total knee replacement surgery. The study was approved
by the ethics committee of Tampere University Hospital.
The donor patients, ages ranging from 66 to 82, were all
diagnosed to have OA. Full thickness pieces of articular
cartilage were removed aseptically from subchondral bone
with a scalpel and cut into small pieces. These pieces of
cartilage were incubated at 37°C in humidified 5% carbon
dioxide atmosphere in Dulbecco’s modified Eagle’s
medium (DMEM) with glutamax-I containing 10% heat-
inactivated fetal bovine serum, penicillin (100 units/ml),
streptomycin (100 g/ml) and amphotericin B (250 ng/ml)
(all obtained from Gibco BRL, Paisley, U.K.). NO produc-
tion was induced by IL-1, TNF, LPS or IL-17. The concen-
trations used were chosen to induce about similar level of
NO production based on our previous dose response
studies36, in the case of IL-17 found in the literature37.
J774 murine macrophages (American Type Culture Col-
lection, Rockville, U.S.A.) were used as reference cell line
in some studies. J774 cells were cultured under similar
conditions and harvested with trypsin-EDTA (ethylenedi-
aminetetraacetic acid; Gibco BRL, Paisley, U.K.).NITRITE DETERMINATION
The culture medium was collected after the time indi-
cated and nitrite, a stable product of NO in aqueous
solutions, was measured using the Griess reaction as
previously described38. Tissue pieces were weighed and
results were expressed as pmol of nitrite/mg tissue.ELISA
Aliquots of the culture media were kept at −20°C until
assayed. The concentrations of TNF, sTNFRI and
sTNFRII were determined by ELISA using reagents from
Central Laboratory of the Netherlands Red Cross Blood
Transfusion Service, Amsterdam, the Netherlands (TNF)
and R&D Systems, Inc., Minneapolis, U.S.A. (Quantikine
Human sTNFRI and sTNFRII Immunoassay).WESTERN BLOT ANALYSIS
Frozen cartilage specimen milled with Micro-
Dismembrator and cell pellets from J774 cells were lysed in
ice-cold extraction buffer (10 mM Tris-base, 5 mM
ethylenediaminotetra-acetate (EDTA), 50 mM NaCl, 1%
Triton-X, 0.5 mM phenylmethylsulfonylfluoride, 2 mM
sodiumorthovanadate, 10 g/ml leupeptin, 25 g/ml apro-
tin, 1.25 mM NaF, 1 mM sodiumpyrophosphate, 10 mM
n-octyl-beta-D-glucopyranoside; all from Sigma, St Louis,
U.S.A.). Following incubation in ice for 15 min, samples
were centrifuged and the resulting supernatant was boiled
for 5 min in four volumes of sample buffer (6.25 mM Tris-
HCl, 10% glycerol, 2% SDS and 0.025% 2-mercapto-
ethanol; all from Sigma, St Louis, U.S.A.) and stored at
−20°C until analysed. Coomassie blue method was used to
measure the protein content of the samples39. Protein
samples (10 g) were separated by SDS-PAGE on 8%
polyacrylamide gels and transferred to nitrocellulose
membrane (Hypond-ECL, Amersham International,Buckinghamshire, U.K.). The nitrocellulose was blocked
with non-fat dry milk. iNOS protein was identified by
Western blot using rabbit polyclonal iNOS antibody (N-20)
obtained from Santa Cruz Biotechnology, Santa Cruz,
U.S.A. This antibody is raised against a peptide corre-
sponding to an amino acid sequence mapping the amino
terminus of human iNOS. It reacts with iNOS of mouse, rat
and human origin and there is no cross-reactivity with
neuronal or endothelial NOS. The filter was developed
using the ECL® Western blot detection system (Amersham
International, Buckinghamshire, U.K.) and then exposed to
film (Kodak Biomax). The molecular weight was estimated
using Precision-marker (Precision Prestained Standards;
Bio-Rad, Hercules, U.S.A.).STATISTICAL ANALYSIS
Results are expressed as mean±standard error of the
mean (S.E.M.). Statistical significance was calculated using
Student’s paired t-test and repeated measures of ANOVA
supported by Bonferroni multiple comparisons test.
Differences were considered significant when P<0.05,
unless stated otherwise.REAGENTS
Etanercept (Enbrel®; Wyeth Lederle, Finland), infliximab
(Remicade®; Schering-Plough, Finland), IL-1 (Genzyme,
Cambridge, U.S.A.), TNF (Immugenex Corp., Los
Angeles, U.S.A.), bacterial lipopolysaccharide (LPS;
Sigma, St Louis, U.S.A.) and L-N-iminoethyl-ornithine
(L-NIO; Glaxo Wellcome, Stevenage, U.K.) were obtained
as indicated. IL-17, anti-human sTNFRI and sTNFRII neu-
tralizing antibodies as well as mouse IgG1 isotype control
were obtained from R&D Systems, Inc., Minneapolis,
U.S.A.ResultsEFFECTS OF TNF ON NO PRODUCTION IN OA CARTILAGE
TNF (0.4–40 ng/ml) stimulated nitrite production in
osteoarthritic cartilage in a dose dependent manner. A
non-selective NOS inhibitor L-NIO (1 mM) prevented
TNF-induced nitrite accumulation, indicating that it was
due to NO production [Table I]. Table II shows that NO
production in response to TNF was linear up to 72 h
follow-up. In the further studies, Western blot analysis was
carried out with an antibody against human iNOS which
reacts with mouse, rat and human iNOS but not with
neuronal or endothelial NOS. In cartilage pieces treated for
48 h with TNF (40 ng/ml) a clear immunoreactive band
was seen in Western blot analysis, and it was of similar MW
as iNOS in LPS-treated J774 murine macrophages (Fig. 1).
Osteoarthritic cartilage incubated in the absence of TNF
also expressed iNOS but at a lower level than TNF-
treated cartilage.EFFECTS OF TNF-ANTAGONISTS ON NO PRODUCTION IN OA
CARTILAGE
To study the effects of TNF-antagonists we used clini-
cally achievable concentrations of infliximab (0.1–100 g/
ml; cmax in serum 118 g/ml40) and etanercept (1–1000 ng/
ml; c in serum 1.2 g/ml31). The effects of infliximab andmax
Osteoarthritis and Cartilage Vol. 10, No. 4 329etanercept were studied on TNF (40 ng/ml), IL-1 (4 ng/
ml), IL-17 (100 ng/ml) and lipopolysaccharide (LPS; 1 g/
ml) induced NO synthesis in osteoarthritic cartilage.
Infliximab and etanercept inhibited TNF-induced NO pro-
duction in a concentration-dependent manner [Fig. 2(a)].
The inhibitory effect was also shown in Western blot
analysis, which confirmed suppression of iNOS expression
by infliximab and etanercept in TNF-stimulated cartilage
(Fig. 1). In contrast, spontaneous NO production or that
induced by IL-1, IL-17 or LPS was not altered by infliximab
or etanercept [Fig. 2(b)].TNF AND SOLUBLE TNF RECEPTORS
Osteoarthritic cartilage produced TNF (2.4±0.5 pg/
100 mg tissue/42 h; N=6) measured by ELISA in the cul-
ture medium. The cartilage explants released also soluble
TNF receptors which function as endogenous TNF
antagonists. Soluble TNF receptor I (sTNFRI) concen-
tration following 42 h incubation was 215.0±18.3 pg/
100 mg tissue and receptor II (sTNFRII) concentration
605.7±184.6 pg/100 mg tissue. A neutralizing antibody
against soluble TNFRI enhanced spontaneous NOproduction by 124%. In contrast, an antibody against
soluble TNFRII or control IgG had no effect (Fig. 3).Discussion
The main feature in the pathogenesis of OA is the
cartilage breakdown due to slowly progressing inflamma-
tory reaction. In this process cytokines, especially IL-1 and
TNF, act as significant destructive mediators1. We
focused our study on TNF which has been reported to be
present in synovial fluid of patients with clinically active
OA41,42. Although concentrations detected in synovial fluid
are low in OA as compared with RA, there is increasing
evidence that TNF has a significant role in the pathogen-
esis of OA43–47. Our study provides a piece of novel
evidence to this clinically important issue. The results show
that both exogenous and endogenous TNF antagonists
regulate NO production in osteoarthritic cartilage.
NO acts as a mediator in various physiological and
pathophysiological processes in the body48. In inflamed
joints, NO plays a role as a proinflammatory and destruc-
tive mediator12–21. The present study confirms that spon-
taneous production of NO through iNOS pathway was
enhanced by TNF and IL-1 as well as by IL-17 and LPS.
Considering the importance of NO in cartilage destruction,
we chose to study the role of TNF in this perspective.
Anti-TNF-therapy is clinically used in RA. Only one
report was found where these TNF-antagonists were
studied in respect to NO: Perkins et al. reported that
treatment with anti-TNF monoclonal antibody resulted in
reduction of iNOS overexpression in RA patients33. We
could not find any reports on anti-TNF-trials on OA modelsTable I
Concentration-dependent effect of TNF on NO production in
human osteoarthritic cartilage
TNF
concentration
(ng/ml)
Nitrite (pmol/mg tissue)
TNF TNF+L-NIO (1 mM)
0 102±14 73±15*
0.4 149±29†
4 215±39†
40 327±35††† 68±20***
Cartilage explants were cultured for 48 h with indicated concen-
trations of TNF.
Nitrite was measured in the culture medium as an indicator
of NO synthesis and expressed as pmol nitrite/mg tissue.
Mean±S.E.M., seven patients (=N), each with six parallels.
Statistical significance was calculated with Student’s paired
t-test.
†P<0.1, ††P<0.01, †††P<0.001, compared to spontaneous NO
production, i.e. in the absence of exogenous TNF.
*P<0.1, ***P<0.001, compared to TNF stimulated NO produc-
tion in the absence of NOS inhibitor L-NIO.Table II
Time-dependent effect of TNF on NO production in human osteoarthritic cartilage
Incubation
time (h)
Nitrite (pmol/mg tissue)
Spontaneous
production
TNF
(40 ng/ml)
TNF (40 ng/ml)
+L-NIO (1 mM)
8 21± 8 41±11† 17± 7*
24 55±15 146±15†† 40±14***
48 102±14 327±35††† 68±20***
72 171±18 482±33††† 124±23***
Nitrite was measured in the culture medium as an indicator of NO synthesis and expressed as pmol nitrite/mg
tissue. Mean±S.E.M., seven patients (=N), each with six parallels.
Statistical significance was calculated with Student’s paired t-test.
†P<0.1, ††P<0.01, †††P<0.001, compared to spontaneous NO production, i.e. in the absence of exogenous
TNF.
*P<0.1, ***P<0.001, compared to TNF stimulated NO production in the absence of NOS inhibitor L-NIO.Fig. 1. iNOS expression in osteoarthritic cartilage as analysed by
Western blot. Osteoarthritic cartilage specimens were incubated
for 42 h in the absence of exogenous cytokines (lane 2), with TNF
(40 ng/ml; lane 3), with TNF and infliximab (100 g/ml; lane 4),
with TNF and etanercept (1 g/ml; lane 5). J774 macrophages
stimulated with LPS for 12 h were used as a positive control (lane
1). A representative experiment of three with similar results.
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IgG1)31. Both TNF-antagonists, at clinically achievable
concentrations, suppressed TNF induced iNOS expres-
sion and NO production in a concentration-dependent
manner indicating that infliximab and etanercept are func-
tionally active and penetrate into human osteoarthritic car-
tilage. The TNF antagonists did not inhibit NO production
induced by IL-1, IL-17 or LPS. This finding suggests that
TNF is not an autacoid mediator in these processes.
The effects of TNF are mediated through two cell
surface receptors, i.e. type I (55-kD, p55) and type II
(75-kD, p75) receptors. Both of these receptors may also
be released from the cell membrane by proteases. These
soluble receptors are able to bind TNF and function as
endogenous TNF antagonists49. In OA chondrocytes p55
receptor has been reported to be the predominant receptorype, although both receptors have been found to be
xpressed constitutively and are differently distributed in
he same knee47,50,51. Osteoarthritic synovial fluid has
een shown to up-regulate expression of p55 in non-
rthritic chondrocytes45. Focal loss of cartilage and pres-
nce of p55 receptor have been reported to be related with
ncreased glycosaminiglycan (GAG) release in response
o TNF-treatment43,47. In addition, enhanced expression
f TNF convertase enzyme (TACE) has been found in
steoarthritic cartilage. TACE is a proTNF cleaving
etalloprotease, which provides a further extension to
omplex TNF regulatory network44,46.
In the present study, TNF and its soluble receptors
NFRI and TNFRII were measured in the culture medium
y ELISA. Osteoarthritic cartilage produced TNF and
oluble TNFRI and TNFRII. We used neutralizing anti-
odies against soluble TNF receptor I (sTNFRI) and II
sTNFRII) to test their possible effect on spontaneous NO
roduction. The results show that if TNFRI is blocked by
eutralizing antibody, NO production increases signifi-
antly. This suggests that endogenous TNF-antagonists
soluble TNFRI) down-regulate destructive effects of TNF
n osteoarthritic cartilage.
These data provide evidence to suggest that endogen-
us TNF plays a role in the pathogenesis of OA and that
NF-antagonists may have beneficial effects on osteo-
rthritic cartilage.0
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Fig. 2. (a): The dose-dependent effects of infliximab and etaner-
cept on TNF (40 ng/ml)-induced nitrite production in osteoarthritic
cartilage. NOS inhibitor L-NIO (1 mM; the black bar) was used as
a control compound. Mean±S.E.M., 13–14 patients (=N), each with
three parallels. (b): The effects of infliximab (100 g/ml; ) and
etanercept (1 g/ml; ") on spontanenous (medium), and on IL-1
(4 ng/ml)-, LPS (1 g/ml)- and IL-17 (100 ng/ml)- induced nitrite
production (h). Mean±S.E.M., 4–6 patients (=N), each with three
parallels. In (a) and (b), the explants were cultured for 42 h.
Statistical significance was calculated with repeated measures of
ANOVA. *P<0.05, **P<0.01 and ***P<0.001 as compared to the
control without TNF-antagonist.0
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